AURKA and acute myeloid leukemia: AT9283, a small molecule inhibitor of Aurora kinases A and B, c-ABL, JAK2 and other kinases caused HTN as a dose-limiting toxicity in an open-label, dose-escalation study investigating this agent in the treatment of refractory AML and advanced PMF/SMF [85].